Delcath Systems Inc

NASDAQ:DCTH  
11.96
+0.69 (+6.12%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)81.53M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$0.73 Million
Adjusted EPS-$1.00
See more estimates
10-Day MA$11.28
50-Day MA$11.56
200-Day MA$14.26
See more pivots

Delcath Systems Inc Stock, NASDAQ:DCTH

1633 Broadway, Suite 22 C, New York, New York 10019
United States of America
Phone: +1.212.489.2100
Number of Employees: 36

Description

Delcath Systems, Inc. is an oncology company, which focuses on the treatment of primary and metastatic liver cancers. It develops and commercializes CHEMOSAT and Melphalan Hydrochloride for Injection, which is a proprietary product used with the Delcath Hepatic Delivery System. The company was founded in August 1988 and is headquartered in New York, NY.